Related Experiment Videos
Tolerability and antidepressive effect of brofaromine, a short-acting reversible MAO inhibitor--an open study
1Department of Neurology, University of Essen, Germany.
Abstract:
The tolerability and antidepressive effect of brofaromine, a selective MAO-A inhibitor was tested in 14 depressive patients. None of the patients showed blood pressure or pulse frequency changes after ingesting tyramine-enriched meals. Four instances of agitation were observed as side effects. In two of these cases, the appearance of paranoid thinking and suicidal tendencies led to premature termination of the study. In 3 cases sleep disturbances, in particular difficulties in falling asleep, were observed. In the test of antidepressive effectiveness (measured on the HAMD-scale) significant improvement was observed from day 14 onwards.
Insights
Brofaromine, a selective monoamine oxidase A (MAO-A) inhibitor, showed antidepressant effects in patients. While generally well-tolerated, some experienced agitation and sleep disturbances, necessitating study termination in two cases.
Area of Science:
- Pharmacology
- Psychiatry
- Clinical Medicine
Background:
- Selective monoamine oxidase A (MAO-A) inhibitors represent a class of antidepressants.
- Understanding the tolerability and efficacy of novel MAO-A inhibitors is crucial for treating depression.
Purpose of the Study:
- To evaluate the tolerability and antidepressant effects of brofaromine, a selective MAO-A inhibitor.
- To assess the safety profile of brofaromine in patients with depression.
Main Methods:
- A study involving 14 depressive patients.
- Administration of tyramine-enriched meals to assess cardiovascular response.
- Evaluation of antidepressive effectiveness using the Hamilton Depression Rating Scale (HAMD).
Main Results:
- No significant changes in blood pressure or pulse frequency were observed after tyramine ingestion.
- Four patients experienced agitation; two discontinued due to paranoid thinking and suicidal tendencies.
- Three patients reported sleep disturbances, specifically difficulty falling asleep.
- Significant improvement in depressive symptoms was noted from day 14 onwards on the HAMD scale.
Conclusions:
- Brofaromine demonstrates antidepressant efficacy in patients with depression.
- While generally safe regarding tyramine interaction, potential side effects include agitation and sleep disturbances.
- Further research may be warranted to optimize brofaromine's use and manage its side effects.